Skip to main content
PLOS One logoLink to PLOS One
. 2025 Jul 14;20(7):e0323275. doi: 10.1371/journal.pone.0323275

Process evaluation for the STAMINA randomised controlled trial: A protocol

Saïd Ibeggazene 1,*, Sophie Reale 1, Alison Scope 1, Grace Price 1, Eileen Sutton 2, Liam Bourke 1, Michelle Collinson 3, Jamie Stokes 3, Liz Steed 4, Derek Rosario 5, Amanda J Farrin 3, Steph JC Taylor 4
Editor: Xing-Xiong An6
PMCID: PMC12258564  PMID: 40658661

Abstract

Background

STAMINA is a randomised controlled trial of a complex lifestyle intervention incorporating exercise prescription into a prostate cancer care pathway. The 12-month intervention aims to improve disease specific quality of life and reduce fatigue of people receiving androgen deprivation therapy for prostate cancer. Previously published work outlines the development of the trial intervention which included recruitment and training of healthcare professionals and exercise professionals to embed a lifestyle intervention and referral pathway within NHS prostate cancer care.

Methods

A mixed-methods process evaluation, embedded within the STAMINA trial, will be conducted to assess quantitative process outcomes (recruitment, intervention reach, dose and fidelity), together with up to 45 qualitative interviews with patients, healthcare professionals and exercise professionals. Interviews will explore the perceptions and experiences of those involved in the STAMINA trial, and the organisational implications of embedding and sustaining the intervention. Quantitative process data will be analysed descriptively. Qualitative interview data will be analysed before trial outcomes are known using an inductive and deductive approach. Findings from the different elements will be reported separately and then integrated to inform interpretation of trial outcomes.

Conclusion

This process evaluation protocol provides a detailed description of relevant data collection methods and trial processes of the STAMINA randomised controlled trial which will allow us to determine whether the intervention can be delivered with fidelity, is acceptable to patients, healthcare professionals and exercise professionals, and understand the implications for embedding and sustaining the intervention in the routine care.

Trial registration

ISRCTN 46385239, registered on 30/07/2020. Cancer Research UK 17002, retrospectively registered on 24/08/2022.

Background

Prostate cancer is a long-term condition which is estimated to affect more than 1.4 million people globally [1], a figure which is projected to double by 2040 [2]. In the UK, like many developed countries, prostate cancer is the most common male cancer and its prevalence is projected to increase until 2035 at least, whilst prostate cancer-related mortality rates continue to decline [3]. Consequently, the prostate cancer survivorship population is likely to continue to expand. Though the impact of prostate cancer on a person’s life varies substantially, advances in prostate cancer treatment have reduced mortality, meaning much of the impact of living with prostate cancer is iatrogenic in nature.

A key effective treatment of advanced prostate cancer is androgen deprivation therapy (ADT) which can be administered for up to two decades in combination with shorter courses of other treatments including radiotherapy, chemotherapy, and androgen receptor inhibitors. Notwithstanding the negative sequelae of other treatments, ADT is associated with increased burden of adverse effects including: fatigue, fat mass gain, loss of lean mass, hot flushes, bone fracture risk, diabetes, cognitive dysfunction, depression and sexual dysfunction [4]. Individuals may experience one or many of these effects leading to negative impacts on quality of life. At present, the only evidence-based intervention to improve quality of life and fatigue in this population is supported exercise training [5]. This has led to 12 weeks of supported aerobic and resistance exercise training being recommended for people receiving ADT in national and international guidelines [6,7]. Despite this, access to such a service in the UK is extremely scarce [8].

To address this need, we undertook a programme of work with the aims of defining, developing, implementing, and evaluating a complex lifestyle intervention incorporating exercise prescription into a care pathway for people receiving ADT for prostate cancer. We intended for the intervention to be embedded within NHS prostate cancer care pathways and implementable across the UK. The culmination of this work is the STAMINA randomised controlled trial (RCT). This paper describes the protocol for the parallel process evaluation.

Trial Status

The RCT protocol has been published [9] (ISRCTN 46385239, registered on 30/07/2020. Cancer Research UK 17002, retrospectively registered on 24/08/2022). 700 participants were recruited between January 2022 and June 2023 and the trial is now in follow-up. Results of the clinical effectiveness and economic evaluations of the STAMINA intervention will be made available once trial follow-up is complete.

The STAMINA randomised controlled trial

The STAMINA RCT is investigating the clinical and cost effectiveness of a 12-month lifestyle intervention for men receiving ADT for prostate cancer. We hypothesise that the intervention will improve disease-specific quality of life and/or reduce fatigue after 12 months (FACT-Prostate [10] & FACIT-Fatigue [11] questionnaires, respectively). The trial will also assess whether the intervention has an impact on blood pressure, body mass, physical function, abdominal adiposity, self-reported physical activity, behavioural determinants of exercise behaviour, fear of cancer recurrence and the burden of side effects from ADT.

NHS healthcare professionals at participating sites were invited to receive training to enhance their knowledge, skills, and confidence regarding endorsing exercise to this population during usual care in line with NICE guidance prior to participant recruitment. All participants received a standardised purpose-made information booklet with information about exercise and dietary recommendations for this population plus related booklets from UK cancer charities [1215]. Accordingly, the control is described as optimised usual care (OUC). Trial participants are randomised to receive OUC or the STAMINA lifestyle intervention (SLI + OUC).

The STAMINA lifestyle intervention

The STAMINA lifestyle intervention (SLI) is a complex intervention facilitated by NHS healthcare professionals (HCPs) and exercise professionals (EPs) from Nuffield Health fitness centres. The development and refinement of the complex intervention components have been published previously [1618]. In brief, intervention development was underpinned by the Theoretical Domains Framework [19] and guided by the Behaviour Change Wheel [20,21]. Complimentary stakeholder workshops were delivered to ensure future implementation was considered at all stages of development and refined based on Normalisation Process Theory (NPT) [22].

Both HCPs and EPs receive bespoke behaviourally informed training and ongoing support to enable them to jointly (but separately) implement the intervention. In this way, there are three components to the complex intervention that coalesce to produce the intended changes in participant outcomes.

We have developed a logic model (Fig 1) which outlines the assumed causal chain of events in SLI.

Fig 1. STAMINA programme logic model.

Fig 1

Healthcare professional training

Healthcare professionals from NHS Urology and Oncology departments (including clinical nurse specialists, consultants, radiographers, and prostate cancer support workers) were recruited and trained to refer NHS patients who were receiving ADT for prostate cancer to the trial and to endorse and support patients to exercise. Trained HCPs have the potential to influence participants exercise behaviours prior to randomisation, this component of the intervention was deemed necessary for the successful implementation of SLI. Ongoing support for participants to exercise is provided as routine clinical appointments.

A behaviourally informed training package underpinned by the Theoretical Domains Framework [19] was developed for HCPs to support the delivery of NICE recommendations including identifying eligible patients suitable for exercise, recommending exercise, providing information, making an exercise referral and providing support [16]. The training package was delivered at site or remotely via video-conference in an up to three-hour interactive training package. NHS staff received ongoing support from the intervention training team.

Exercise professional training

A range of staff (including front-of-house staff, management, and the fitness team) at Nuffield Health sites were invited to complete three short online training modules providing introductory content regarding who the intervention was designed for and how to operationalise the intervention locally. Subsequently, the fitness team were invited to a full day interactive training session to develop their skills, knowledge, and confidence to deliver SLI. Upon satisfactory completion of training, EPs were designated the title of Clinical Exercise Specialist (CES). The CES role included providing an induction to the gym, delivering supervised exercise and behavioural support to trial participants and recording data in line with the trial protocol. Nuffield Health staff received ongoing support from the intervention training team.

The participant STAMINA lifestyle intervention

The published trial protocol provides a full description of the intervention [9].Participants randomised to SLI are provided with an induction to the gym and facilities, 12 weeks of twice weekly scheduled individually tailored supervised exercise, a review of progress with behavioural support at weeks 2, 4, 6 and 12 and every three months thereafter and 3–9 scheduled supervised exercise sessions over the remaining nine months of the programme (during which time the participant is encouraged to independently exercise twice weekly). The first 12 “weeks” of the programme can be completed over a 14-week period to allow for a run-in period whereby the intensity/volume/frequency of sessions may begin below the initial recommended prescription and gradually increase to the full prescription. The degree of reduction of the prescription and the rate of increase in prescription parameters is at the discretion of the CES responsible for the participant. Sessions in this period are initially delivered on a one-to-one basis but are progressed to group exercise when the CES deems the participant to require less intensive supervision. Modification of the programme will be considered for individual cases (e.g. to provide remote sessions). Each participant may receive supervision from multiple members of the CES team during the intervention. Exercise sessions generally last 60 minutes and include 30–45 minutes of aerobic exercise and up to four sets of resistance exercises for major muscle groups.

Process evaluation

This protocol outlines an embedded parallel process evaluation to the STAMINA trial which was designed following initial intervention development work and a pre-pilot study [1618].

Aims and objectives

The aims of this process evaluation are:

  • To understand trial recruitment performance.

  • To describe intervention reach, dose delivered, and dose received.

  • To describe the fidelity of intervention delivery.

  • To understand how the intervention was experienced and understood by patients using semi-structured interviews (underpinned by the Theoretical Framework of Acceptability).

  • To explore the organisational implications for embedding and sustaining the intervention in preparation for wider NHS roll-out using semi-structured interviews (underpinned by consideration of Normalization Process Theory).

Methods

Informed by MRC guidance on evaluation of complex interventions and process evaluation and the Linnan and Steckler process evaluation framework [2325], we are undertaking a mixed-methods process evaluation. All process evaluation data will be collected prospectively and without knowledge of trial outcomes, either by participants or evaluators. Ethics approval was granted West of Scotland Research Ethics Committee (1 20/WS/0069) and written, informed consent to participate will be obtained from all participants. Members of the process evaluation team are involved in the delivery of the trial. SI, SR, AS and GP were involved in contacting and consenting (SI & GP) prospective trial participants. SR is responsible for providing training and intervention support to EPs and conducting interviews with HCPs and trial participants. AS is responsible for providing training and intervention support to HCPs and conducting interviews with EPs and trial participants. SI is responsible for delivering safety to exercise checks and defining tailored exercise parameters for participants randomised to SLI.

A summary of the process evaluation components which will be targeted for data collection have been mapped against the key components of process evaluation according to Linnan and Steckler [25] (Table 1). Table 2 lists the data collection methods used, with each method cross-referenced to the process evaluation components which they address in Table 1. The timescales for these process evaluation methods have been mapped onto the main trial timescales and detailed in Appendix 1.

Table 1. Process evaluation components.

MRC/ Linnan & Steckler component Participant intervention Healthcare professional training Exercise professional training
Recruitment •1) Numbers of participants screened and their characteristics: treatments, type of ADT, other PCa treatments, age, ethnicity, referral pathways. •22) Number of potential NHS STAMINA sites and data related to site eligibility
•23) Number of sites who agree to be part of STAMINA and approve recruitment to begin
•24) Reasons given by sites for refusal to participate
•25) Characteristics of NHS sites recruited e.g. size, patient capacity, hospital type, rural vs urban, NH partner site nearby etc.
•26) Number of sites willing to take part vs. number of sites recruited
•27)NHS primer meeting attendance (invited vs. attended)
•40) Number of NH sites made available to STAMINA trial by NH and number partnered with NHS site
•41) Characteristics of NH sites involved in STAMINA (e.g. location in relation to NHS site, size of fitness team (no. of EPs on site), are
sites delivering on other internal NH ‘flagship programmes’ etc.
•42) NH primer meeting attendance (invited vs. attended)
•43) Number of NH EPs in NH sites
Reach •2) Number/proportion of men referred to study team
•3) Number of men on ADT interested in participating in STAMINA
•4) Reasons for ineligibility/ not interested in participating (if provided)
•5) Number of participants eligible
•6) Number of participants consented and randomised
•7) Characteristics of randomised participants
•28) Take up of training of HCPs in intervention sites, including characteristics and proportions of those invited vs. those attending (urology vs. oncology staff, consultant vs. nurse or other HCP etc). •44) Total number of NH staff attending training
•45) Characteristics of EPs undergoing and passing training including length of time at NH, as EP, qualifications, previous experience with clinical populations, experience with flagship programmes and any remote delivery experience
Dose delivered •8) Number of supervised sessions and reviews offered by Nuffield Health staff •29) Number of training sessions delivered per site and per staff member
•30) Descriptions of training delivery: when and in which sites training was delivered, training duration, mode of delivery, attendance, number of follow-up training sessions delivered etc.
•31) Training facilitator characteristics
•32) Follow-up intervention support provided
•46) Number of training sessions delivered per site and per staff member
•47) Descriptions of training delivery: when and for which sites training was delivered, training duration, mode of delivery, attendance, staff turnover, number of follow-up training sessions delivered, attendance etc.
•48) Training facilitator characteristics
•49) Follow-up intervention support provided
Dose received •9) Number of participants actually receiving the supervised intervention
•10) Supervised exercise dose: Number of supervised training sessions attended, exercise intensity, aerobic exercise duration, resistance training volume
•11) Intervention and delivery format (i.e. number and proportion of face-to-face vs remote sessions, number and proportion of group vs 1-2-1 sessions)
•12) Details of (unsupervised) gym use and other physical activity by intervention participants
•13) Behavioural support diary completion
•14) Progress/summary report produced by CESs including number, timeliness, content and any evidence it has been acted on by HCPs
•33) Assessment of change in behavioural determinants impacted/ targeted by the intervention
•34) Engagement with follow-up support
•50) Assessment of change in behavioural determinants impacted/ targeted by the intervention
•51) Engagement with follow-up support
Fidelity •15) Digital audio recordings of CES: patient induction and review sessions (from a sub-sample of N = 5 sites).
•16) Direct observations of CESs delivering supervised sessions (up to a maximum of 30 observations)
•17) Video recording of remote intervention delivery sessions
•35) Video recording of HCP training delivery •52) Video/audio recording of CES training delivery
Implementation •18) Adverse event reporting
•19) Intervention dropout rates and reasons for dropout
•20) Participants experience of ADT
•21) Interviews exploring the acceptability of the STAMINA lifestyle intervention to participants
•36) Recording the length of delay between receipt of training and first delivery of intervention
•37) Interviews exploring perceptions and experiences of those involved in STAMINA, and the organisational implications of embedding and sustaining the intervention in preparation for a wider NHS roll-out of the programme.
•38) Field notes following HCP training delivery
•39) Field notes of support interactions with NHS teams
•53) Recording the length of delay between receipt of training and first delivery of intervention
•54) Number of participants seen by each CES
•55) Format and amount of the participant intervention delivered by each CES
•56) Length of time CESs remain in study delivering intervention
•57) Reasons for CES discontinuation in trial (if applicable)
•58) Interviews exploring the perceptions and experiences of those involved in STAMINA, and the organisational implications of embedding and sustaining the intervention in preparation for a wider NHS roll-out of the programme.
•59) Field notes

ADT– Androgen Deprivation Therapy, CES – Clinical Exercise Specialist, EP – Exercise Professional, HCP – Healthcare professional, NH – Nuffield Health, NHS – National Health Service, PCa – Prostate Cancer.

Table 2. Process evaluation data collection methods.

Data collection methodology Target population Data collection methods (components)
Qualitative analysis Participants • Behavioural support diary completion (13)
• Participant interviews (21)
Exercise professional team • Interviews (58)
• Video/audio recordings of intervention training (52)
• Direct observations of CESs delivering supervised sessions (16)
• Audio recordings of CESs delivering review sessions (15)
• Remote supervised exercise session recordings (17)
• Intervention support log (49, 51)
• Field notes (59)
Healthcare professional team • Interviews (37)
• Video recordings of intervention training (35)
• Intervention support log (32, 34)
• Field notes (38–39)
Quantitative analysis Participant • Screening logs at site (1, 2)
• Referrals processing databases and CRFs (2–6,36)
• Baseline participant characteristics CRF (7)
• Participant withdrawal CRF (19)
• Adverse Event reporting (18)
• ADT symptom index (20) – S1 File
• Godin Leisure-time exercise questionnaire (12)
• Participant intervention logbooks (8–11, 53–56)
• Swipe card data (logs of swipes of a membership card to access the gym) (12)
• Progress/summary reports (14)
Exercise professional team • Nuffield Health site screening log (40)
• Nuffield Health site characteristics CRF (41)
• Training facilitator characteristics CRF (48)
• Meeting and Training attendance logs (42–44, 46, 47,51)
• EP personal details CRF (45)
• EP Theoretical Domains Framework questionnaires (50)
• Authorised personnel logs (56–57)
Healthcare professional team • Site feasibility questionnaires (22–26)
• Training facilitator characteristics CRF (31)
• Meeting and Training attendance logs (28–30)
• HCP personal details CRF (28)
• HCP Theoretical Domains Framework questionnaires (33)

ADT – Androgen Deprivation Therapy, CES – Clinical Exercise Specialist, CRF – Case Report Form, EP – Exercise Professional, HCP – Healthcare professional, TDF – Theoretical Domains Framework.

Qualitative data descriptions and analysis

Interview method.

We will conduct one to one interviews (telephone or face to face) or focus groups (depending on interviewee preference and feasibility) with a purposive sample of up to: 15 SLI participants, 10 OUC participants; 10 CESs and 10 HCPs. Interviews and focus groups will be conducted at different times across the trial to help capture any temporal effects (including referral and reporting processes). Topic guides have been developed in accordance with the NPT (for professional interviews) and Theoretical Framework of Acceptability (TFA) [26] (for trial participant interviews) to explore implementation and acceptability of the intervention respectively. The same questions will be asked to SLI and OUC participants except for questions specific to the intervention which will be omitted for those in the OUC arm. All participants must provide consent and remain in the trial before interview/focus group. Copies of the topic guides can be found in the Supplementary materials.

Interviews will be audio recorded, following agreement from the interviewee, using an encrypted dictaphone and will be professionally transcribed. During transcription, any potentially identifying information that may be contained in the interview discussions will be anonymised or removed. Only the research team and the transcriber will listen to the interview audio files and have access to the transcripts. All audio files, transcripts and field notes will be securely transferred and stored in encrypted format, accessible only to members of the study team requiring such access.

Interview sampling.

Participants will be purposively sampled based on their age, geographical location, and stage of the intervention/duration of follow-up. SLI participants will also be purposively sampled based on their adherence to the intervention (e.g., low, moderate, or high).

CESs will be eligible for interview once they have completed intervention training and delivered at least 12 weeks of supervised exercise to five or more participants. CESs will be purposively sampled based on details collected during staff training (i.e., role, geographical location, tier of club, gender, experience).

HCPs will be eligible for interview once they have completed intervention training. HCPs will also be purposively sampled based on details collected as part of staff training (i.e., role, speciality, geographical location, hospital type, experience).

Interview analysis.

We will take an inductive and deductive approach to thematic analysis guided by Braun and Clarke’s six phases [27]. NPT constructs and sub-constructs (Table 3) will provide the framework for analysis of professional interviews whilst the TFA (Table 4) will provide the framework for participant interviews [26]. We will also consider data that falls outside of the priori codes to derive themes and concepts. At least 20% of data will be independently double or triple coded. Decisions, disagreements, and development of the frameworks will be documented in a coding manual at every phase of analysis. Once the transcripts have been coded, for each of the three participant groups, all data will be collated into themes either prespecified by the NPT and the TFA or falling outside of these frameworks. There will then be a process of checking to ensure themes work in relation to coded extracts and the entire data set. A thematic map will be generated, followed by ongoing analysis to refine the specifics for each theme [27].

Table 3. Understanding intervention embedding in NHS practice informed by Normalization Process Theory.
Component Example
Coherence Understanding the purpose, value, and benefits of the STAMINA lifestyle intervention, including roles and responsibilities
Cognitive participation Initiating and sustaining buy-in, STAMINA ‘champions’ at NHS sites, individual engagement with STAMINA
Collective action How STAMINA works in day-to-day practice (including roles/resources), communication pathways, work people must do to make STAMINA happen
Reflexive monitoring Appraisal of the benefits and costs of STAMINA, including refinements recommended for a future roll-out
Table 4. Theoretical Framework of Acceptability constructs and example questions.
Theoretical framework of acceptability construct Example
Affective attitude How participants feel about SLI and OUC, including change in feelings over time
Burden The perceived amount of effort required to participate in SLI and OUC, including research related processes
Ethicality How does SLI/OUC align with the participants beliefs and values, including what is important to them
Perceived effectiveness Actual or perceived benefits/outcomes of SLI and OUC, including change over time and any uncertainty related to outcomes
Intervention coherence The extent to which participants understand the trial, and components of SLI/OUC, including information provided by HCPs and EPs
Self-efficacy The participants confidence to perform the required behaviours of SLI and OUC, including confidence to maintain behavioural change
Opportunity costs Anything that participants have missed/given up to participate in SLI or OUC and any reason for non-attendance/ participation
Affective attitude How participants feel about SLI and OUC, including change in feelings over time
Burden The perceived amount of effort required to participate in SLI and OUC, including research related processes

Assessment of fidelity.

Fidelity will be conceptualised in accordance with the National Institute of Health Behavioural Change Consortium framework [28]. This will explore whether the intervention was delivered as intended and the proportion of target behaviours implemented. In multi-site studies, it is particularly important to assess treatment fidelity because if treatment effects vary by site, we can observe whether this is related to variations in the delivery of treatment. For the STAMINA process evaluation, analysis will capture data at three levels: training delivery, training receipt and intervention delivery.

Fidelity: Training delivery.

HCP and EP training will be (digitally or audio) recorded to capture information about how professionals were trained and whether training was standardised across sites. The focus will be on the training facilitators as opposed to the professionals in attendance. Two coding checklists will be developed to assess what was delivered in training (content and behaviour change techniques) compared to what was intended to be delivered as defined by the HCP and EP training manual. Details about facilitator characteristics and how the session was delivered will be captured on paper forms.

Fidelity: Training receipt.

Assessment of cognitive, affective, social and environmental influences of HCP and EP behaviour will be captured in a questionnaire developed based on the TDF [29] (Appendix 2–4). Questionnaires will be distributed immediately prior to training and repeated immediately following training. The questionnaires will be repeated at 3-, 6- and 12-months post training, for EPs, to monitor influences of behaviour over time. We will also record the length of delay between receipt of training and first delivery of intervention.

Fidelity: Intervention delivery.

The gold standard method for capturing fidelity to intervention delivery is coding of digital recordings, evaluated according to criteria developed a priori [30]. We will purposively sample five Nuffield Health fitness and wellbeing clubs (based on their tier, geographical location, facilities, staffing, and experience delivering clinical programmes) and, via an encrypted dictaphone, obtain audio recordings of one-to-one sessions (i.e., inductions and progress reviews) between CESs and SLI participants who have consented to recordings. This method is not feasible for the assessment of supervised exercise sessions that are delivered on a busy gym floor with members of the public in attendance. Therefore, fidelity of supervised exercise sessions will be assessed using pre-specified checklists completed during session observations (either via in person live observation or from a digital session recording) (up to 30 in total) by SR and AS. Checklists will be developed in line with guidance [28] to score adherence and quality of delivery of target behaviours and behaviour change techniques as per protocol. We will also record instances where additional/other behaviours or behaviour change techniques are delivered to allow for evaluation of treatment differentiation. Contemporaneous field notes regarding the context and other related information will be recorded and stored on a secure drive.

Fidelity: Analysis.

Once developed, checklists will be used to score each core behaviour and behaviour change technique between 0 and 2 (0 = not delivered but applicable, 1 = limited delivery, 2 = full/appropriate delivery). If the behaviour is deemed not applicable, then NA will be written. Scores will be summed and converted to a percentage. Levels of treatment fidelity will be interpreted in line with the literature as: 80–100% adherence interpreted as ‘high’ fidelity, 51–79% as ‘moderate’ and 0–50% as ‘low’ fidelity [28,31]. This process will be completed for all recordings of professional training delivery and session observations however for the audio recordings of CES consultations we will analyse a purposive sub-sample [32,33]. The purposive sample will include a minimum data set to reflect 10% of participants receiving SLI and 10% of CESs delivering the intervention and sampling of all time-period interactions. A full sampling framework is detailed in Appendix 5. At least 10% of recordings will be independently coded by two reviewers. A coding manual will be created and updated during piloting and beyond ensuring all key decisions are documented during the analysis.

Quantitative data descriptions and analysis

Analyses of quantitative data will be descriptive in nature. Participant recruitment (rates and characteristics) was monitored via screening logs at site and using routine data (referral outcomes, eligibility, reasons for not taking part, recruitment timelines) from a referrals management system used by the research team. Demographic and clinical characteristics for randomised participants were collected at baseline by trial researchers. Participant withdrawals from the trial or the intervention (including reasons for withdrawal) and related unexpected serious adverse events are recorded by researchers on an ongoing basis during the trial.

Dose monitoring data is drawn from several sources including: participant intervention logbooks, session attendance reports (online form), swipe card data (logs of swipes of a membership card to access the gym) and progress/summary reports produced by CESs including number of sessions prescribed versus attended, timeliness, content and any evidence it has been acted on by HCPs. These data will also allow monitoring of the delivery of the intervention by CESs. Adherence to SLI will be calculated as the number of supervised SLI sessions participants attended as a proportion of those scheduled.

The TDF questionnaires for HCPs (Appendix 3) and EPs (Appendices 2 & 4) will be scored by summing the scores of questions within each domain and dividing by the number of questions within that domain [34]. TDF scores will be reported for questionnaires completed immediately pre and post training and again at 3-, 6- and 12-months post training.

To characterize the NHS sites involved in the trial, prospective sites completed a site feasibility questionnaire, and further characteristics were gathered from publicly available data [35]. Characteristics of the Nuffield health sites were also collected via a case report form which was completed by fitness managers or general managers at site during set-up.

To better understand the implementation of the intervention and training of the two groups of intervention facilitators, data was collected about the delivery of training (training attendance logs, training facilitator characteristics forms) and characteristics of the staff being trained (HCP personal details form, EP personal details form). The length of time CESs remained in the trial delivering the intervention and the reasons for CES discontinuation were recorded where available.

Data synthesis

The mixed-method synthesis will seek to address the aims of this process evaluation, providing explanations for results and recommendations for future practice. The main trial findings will be analysed independently of the process evaluation findings. We aim to produce a high-quality, integrated evaluation of the trial and intervention processes informed by a clear conceptual framework providing evidence to support our interpretations and providing context. Where possible, data from multiple sources will be combined to triangulate our understanding of the process evaluation components (See Table 1). We will use integrated analysis to produce a narrative synthesis drawing upon learning from all data sources to refine the analysis and inform a critical interpretation for the initial programme theory [36]. For example, where appropriate, the qualitative analysis may help us select variables to explore quantitative associations between factors that influence the delivery of the intervention and a participant’s engagement with it. Similarly, descriptive quantitative data may provide important context for qualitative observations and allow for a more informed interpretation.

Limitations

Our process evaluation approach is not without limitations. Context is one process evaluation component from the Linnan and Steckler/MRC framework for which we have not specified the method of formally capturing data, however we anticipate that this will be informed by data from multiple existing sources (e.g., interviews and observations). One limitation of our approach to fidelity concerns the absence of assessment of components of the intervention that are facilitated by HCPs during interactions with participants. In our feasibility study [18], we found collection of audio recordings of conversations between participants and trained HCPs to be difficult to implement in an unbiased manner due to resistance of clinical staff towards recording (and perceived monitoring) of normally confidential conversations and impracticalities around dictaphone use. Another limitation arises from a lack of resource for dedicated, independent process evaluation staff – however funding for such staff is limited by the cost envelope of the study and the inevitable re-distribution of resources following necessary adaptions to the trial design after the COVID pandemic. Many staff in the process evaluation team have been involved in intervention development and trial delivery which has the potential to create biases in the collection and reporting of process evaluation data. In publishing this protocol, we intend to mitigate against the impact of these potential biases by acknowledging their potential in the data collection process for and by making explicit what data is to be collected, how each data type will be used to describe specific process evaluation components and how the process evaluation components and frameworks relate to each other. In addition, the intervention was developed prior to the COVID-19 pandemic, and it was not possible to re-pilot it in a post-pandemic context, thus potential for unanticipated consequences relating to the changes in attitudes towards engaging with the intervention and organisational changes within the NHS or Nuffield Health that took place in this period could not all be anticipated.

Discussion

STAMINA is a complex lifestyle intervention that embeds an exercise prescription within NHS prostate cancer care pathways which is being evaluated in the STAMINA RCT [9]. To better understand the outcomes of the trial and the factors which may have influenced how, and how well, the intervention was delivered, we are conducting a process evaluation. This evaluation will systematically capture qualitative and quantitative data gathered from patients, healthcare professionals, healthcare organisations, exercise professionals and Nuffield Health our exercise delivery partner. We have defined the objectives of this process evaluation and have a clear conceptual framework from which to approach our analysis, however, the diverse and comprehensive choice of data collection methods used may provide us with additional opportunities to explore the “messy realities” that emerge throughout the course of the trial [37] which extend beyond these objectives. The design of this process evaluation will allow us to maximise the usefulness of the STAMINA trial by providing stakeholders and researchers with rich data and comprehensive analysis to understand its outcomes. Should the trial have a positive outcome this process evaluation will allow us the opportunity to provide informed recommendations for intervention implementation ahead of potential future roll-out. Through understanding the strengths and weaknesses of the intervention, how and to what extent it was delivered to and received by participants and how the intervention can be optimised to attain its intended purpose, we aim to provide a clinically and cost-effective exercise referral pathway for men receiving ADT for prostate cancer which improves quality of life and/or reduces fatigue.

Supporting information

S1 File. ADT symptom index.

(DOCX)

pone.0323275.s001.docx (25.6KB, docx)
S2. Appendix 1–5.

(DOCX)

pone.0323275.s002.docx (37.9KB, docx)
S3. STAMINA_Topic_Guide_Interviews_v5.0_20230705.

(DOCX)

pone.0323275.s003.docx (42.7KB, docx)

Acknowledgments

We are very grateful for the substantial contributions made by many to the setting up of this trial and process evaluation: our Sponsor team at Sheffield Teaching Hospitals NHS Foundation Trust; our PSC chaired by Peter Sasieni, and other members Alison Birtle, Richard Bryant and Rachel Elliott; our PMG and STAMINA co-applicants (Patrick Doherty, Jenny Hewison, Janet Brown, David Meads, Diana Greenfield, Dylan Morrissey, Suzanne Hartley and Malcolm Mason); PPIE lay member of our PSC (Geoff Ogden), and PMG/TMG (Tom Baker) who reports on behalf of the PPI Group, co-chaired with John Kidder and Chris Allen; colleagues at the University of Leeds CTRU and Sheffield Hallam University who supported development and implementation of the trial protocol. We are especially grateful to Nuffield Health for their tremendous support in the setting up and delivery of this trial. We would in particular like to thank Aidan Innes and Ben Kelly for their support, and all local Clinical Exercise Specialists and fitness managers.

Data Availability

No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.

Funding Statement

This work is funded by the NIHR Programme Grants for Applied Research (PGfAR) RP-PG-1016-20007. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Consent for publication

For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version of this paper, arising from this submission.

References

  • 1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660 [DOI] [PubMed] [Google Scholar]
  • 2.James ND, Tannock I, N’Dow J, Feng F, Gillessen S, Ali SA. The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet. 2024;403(10437):1683–722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer incidence and mortality projections in the UK until 2035. Br J Cancer. 2016;115(9):1147–55. doi: 10.1038/bjc.2016.304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Nguyen PL, Alibhai SMH, Basaria S, D’Amico AV, Kantoff PW, Keating NL. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. Eur Urol. 2015;67(5):825–36. [DOI] [PubMed] [Google Scholar]
  • 5.Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(4):693–703. [DOI] [PubMed] [Google Scholar]
  • 6.National Institute for Health and Care Excellence [Internet]. Prostate cancer: diagnosis and management NICE guideline [CG175]. 2021. [cited 2024 Jan 9]. https://www.nice.org.uk/guidance/ng131/evidence/full-guideline-pdf-6781033550 [PubMed] [Google Scholar]
  • 7.EAU Guidelines on Prostate Cancer [Internet]. European Association of Urology; 2023. [cited 2024 Jan 9]. https://uroweb.org/guidelines/prostate-cancer/chapter/citation-information [Google Scholar]
  • 8.Bourke L, Turner R, Greasley R, Sutton E, Steed L, Smith D, et al. A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS. PLoS One. 2018;13(7):e0197606. doi: 10.1371/journal.pone.0197606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.McNaught et al. Supported exercise TrAining for Men wIth prostate caNcer on Androgen deprivation therapy (STAMINA): Study protocol for a randomised controlled trial of the clinical and cost effectiveness of the STAMINA lifestyle intervention compared with optimised usual care, including internal pilot and parallel process evaluation; 2023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. Urology. 1997;50(6):920–8. [DOI] [PubMed] [Google Scholar]
  • 11.Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63–74. doi: 10.1016/s0885-3924(96)00274-6 [DOI] [PubMed] [Google Scholar]
  • 12.Macmillan Cancer Support. Macmillan - Healthy eating and cancer MAC13612, Edition 4; 2020. [Google Scholar]
  • 13.Macmillan - Physical activity and cancer MAC12515, Edition 5. Macmillan Cancer Support; 2019. Physical activity and cancer. Macmillan Cancer Support; 2019. [Google Scholar]
  • 14.Prostate Cancer UK. Prostate cancer: A guide if you’ve just been diagnosed. Prostate Cancer UK; 2019. [Google Scholar]
  • 15.Prostate Cancer UK. Living with hormone therapy: A guide for men with prostate cancer. Prostate Cancer UK; 2019. [Google Scholar]
  • 16.Turner RR, Arden MA, Reale S, Sutton E, Taylor SJC, Bourke L, et al. The development of a theory and evidence-based intervention to aid implementation of exercise into the prostate cancer care pathway with a focus on healthcare professional behaviour, the STAMINA trial. BMC Health Serv Res. 2021;21(1):273. doi: 10.1186/s12913-021-06266-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Reale S, Turner RR, Sutton E, Taylor SJC, Bourke L, Morrissey D, et al. Towards implementing exercise into the prostate cancer care pathway: development of a theory and evidence-based intervention to train community-based exercise professionals to support change in patient exercise behaviour (The STAMINA trial). BMC Health Serv Res. 2021;21(1):264. doi: 10.1186/s12913-021-06275-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Reale S, Turner RR, Sutton E, Steed L, Taylor SJC, Morrissey D, et al. Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care: a feasibility and acceptability study (the STAMINA trial). Sci Rep. 2021;11(1):12470. doi: 10.1038/s41598-021-91876-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012;7:37. doi: 10.1186/1748-5908-7-37 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. doi: 10.1186/1748-5908-6-42 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.O’Cathain A, Croot L, Duncan E, Rousseau N, Sworn K, Turner KM, et al. Guidance on how to develop complex interventions to improve health and healthcare. BMJ Open. 2019;9(8):e029954. doi: 10.1136/bmjopen-2019-029954 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Murray E, Treweek S, Pope C, MacFarlane A, Ballini L, Dowrick C, et al. Normalisation process theory: a framework for developing, evaluating and implementing complex interventions. BMC Med. 2010;8:63. doi: 10.1186/1741-7015-8-63 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Moore G, Audrey S, Barker M, Bonell C, Hardeman W, Moore L, et al. Process evaluation of complex interventions: UK Medical Research Council (MRC) guidance; 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021;374:n2061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Linnan L, Steckler A. Process Evaluation for Public Health Interventions and Research. [Google Scholar]
  • 26.Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88. doi: 10.1186/s12913-017-2031-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. [Google Scholar]
  • 28.Borrelli B. The Assessment, Monitoring, and Enhancement of Treatment Fidelity In Public Health Clinical Trials. J Public Health Dent. 2011;71(s1):S52–63. doi: 10.1111/j.1752-7325.2011.00233.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Atkins L, Francis J, Islam R, O’Connor D, Patey A, Ivers N, et al. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implement Sci. 2017;12(1):77. doi: 10.1186/s13012-017-0605-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Walton H, Spector A, Williamson M, Tombor I, Michie S. Developing quality fidelity and engagement measures for complex health interventions. Br J Health Psychol. 2020;25(1):39–60. doi: 10.1111/bjhp.12394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Holcombe A, Wolery M, Snyder E. Effects of two levels of procedural fidelity with constant time delay on children’s learning. J Behav Educ. 1994;4(1):49–73. [Google Scholar]
  • 32.Borrelli B, Sepinwall D, Ernst D, Bellg AJ, Czajkowski S, Breger R, et al. A new tool to assess treatment fidelity and evaluation of treatment fidelity across 10 years of health behavior research. J Consult Clin Psychol. 2005;73(5):852–60. doi: 10.1037/0022-006X.73.5.852 [DOI] [PubMed] [Google Scholar]
  • 33.Toomey E, Matthews J, Hurley DA. Using mixed methods to assess fidelity of delivery and its influencing factors in a complex self-management intervention for people with osteoarthritis and low back pain. BMJ Open. 2017;7(8):e015452. doi: 10.1136/bmjopen-2016-015452 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Grady A, Seward K, Finch M, Fielding A, Stacey F, Jones J. Barriers and enablers to implementation of dietary guidelines in early childhood education centers in Australia: application of the theoretical domains framework. J Nutr Educ Behav. 2018;50(3):229-237.e1. [DOI] [PubMed] [Google Scholar]
  • 35.myhsn.co.uk. What are the different types of NHS hospital? - Health Service Navigator (myhsn.co.uk) [Internet]. [cited 2024 Apr 20]. http://myhsn.co.uk [Google Scholar]
  • 36.Steed L, Rosario D, Taylor SJ, Reale S, Bourke L. STAMINA overarching theory paper [Manuscript in preparation]. 2024.
  • 37.Pragmatic, formative process evaluations of complex interventions and why we need more of them | Journal of Epidemiology & Community Health [Internet]. [cited 2024 Jan 9]. https://jech.bmj.com/content/69/10/925 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Xing-Xiong An

PONE-D-24-40667Process evaluation for the STAMINA randomised controlled trial: a protocolPLOS ONE

Dear Dr. Ibeggazene,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 13 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Xing Xiong, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

This work is funded by the NIHR Programme Grants for Applied Research (PGfAR) RP-PG-1016-20007. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.  

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. Ethics statement only appears at the end of the manuscript:

Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

4. Please include a caption for figure 2.

5. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 5, 6, 7 and 9 in your text; if accepted, production will need this reference to link the reader to the Table. 

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1.Can the authors clarify the rationale behind the chosen mixed-methods process evaluation design and its alignment with the study's objectives?

2. How do the authors ensure the consistency (fidelity) of training and intervention delivery across different sites, especially since the trial involves multiple healthcare professionals and exercise professionals?

3. The study proposes integrating findings from different methods (e.g., interviews, process outcomes). Can the authors provide more specific details about how they plan to triangulate these findings to draw meaningful conclusions?

4. The authors mention some limitations of their approach, particularly regarding fidelity and the absence of audio recordings of healthcare professional-patient interactions. Could the authors elaborate on alternative strategies to mitigate the effects of these limitations?

Reviewer #2: Well designed evaluation study protocol and well written manuscript. Congratulations. Few comments/suggestions are attached

Page 3-Line no-53-56: just wondering whether the listed adverse events would be evaluated pre and post intervention

Page 7 Line no. 150 and 19 and line number -Implementation team doing the process evaluation-Need to incorporate suggestion to strengthen the manuscript-Are these going to be evaluated pre and post intervention?

Page.7: table numbering to be corrected for column as currently number continues from 1 to 59. Each column and row should start with 1

Page 11 -Line no.163: Omission to be rectified-Add ADT

Page 15 Table 4: Suggestion for inclusion--Facilitating factors that helped/induced sustenance of the participants in the programme could be added

Page 15 Table 4: Repetition to be deleted-Affective attitude and burden

Page 15 Line no. 214 to 215: requires rewording for clarity. Cannot understand the statement made. No. of sites will be reduced to maintain treatment fidelity?

Page 17 Line 266: required additional information. If participant doesnt come for follow up intervention, what steps would be taken-could be described

Reviewer #3: The manuscript outlines a protocol for a process evaluation embedded within a lifestyle intervention trial for prostate cancer patients undergoing androgen deprivation therapy (ADT). This evaluation covers recruitment, fidelity, intervention reach, and organizational aspects. Below are some points for clarification and consideration to enhance the transparency and robustness of the evaluation.

Major Comments:

Validity of the Analysis for Endpoints Based on Questionnaires:

The primary endpoints, quality of life and fatigue, rely on self-reported questionnaires (FACT-Prostate and FACIT-Fatigue), which, while validated, may be subject to response bias and measurement variability. How will the study account for the inherent subjectivity and potential variability in self-reported data? Have any sensitivity analyses been considered to assess the robustness of findings against these potential biases?

Timing and Schedule of Endpoint Collection:

The manuscript mentions that process data will be collected at various points during and after the intervention, but it is not entirely clear how this aligns with the timing of the main trial endpoints (e.g., quality of life measured at 12 months). Could the authors clarify the alignment of process data collection with primary trial outcomes? Additionally, given the 12-month follow-up, how will potential attrition bias be managed, particularly in relation to the consistency of data collected from self-reported questionnaires over time?

Fidelity and Intervention Delivery:

The manuscript highlights fidelity assessment as a key component of the process evaluation, utilizing audio recordings, direct observations, and checklists. Could the authors elaborate on how fidelity will be quantified and reported? Will there be a specific scoring system to assess adherence to intervention components? Additionally, how will deviations from the intervention protocol be addressed within the analysis framework?

Bias in Self-Reported Data:

While the process evaluation is comprehensive, it does not address potential bias in the subjective, self-reported data (e.g., physical activity and quality of life outcomes) and qualitative interviews. How will such bias be accounted for in the study, and what impact might this have on the interpretation of the study’s conclusions?

Minor Comments:

Understanding Trial Recruitment Performance:

The process evaluation likely involves tracking recruitment metrics, assessing participant demographics, and gathering qualitative feedback from recruitment staff. Will the evaluation also examine factors that may hinder recruitment, such as through feedback from recruitment staff and potential participants who declined to participate?

Describing Intervention Reach, Dose Delivered, and Dose Received:

Intervention reach, dose delivered, and dose received will be assessed through metrics such as session attendance and participant engagement. Is there a plan to supplement these metrics with qualitative feedback from participants, such as through exit interviews or surveys, to provide more context on adherence challenges?

Exploring Organizational Implications for Embedding and Sustaining the Intervention:

Semi-structured interviews with HCPs, guided by the Normalization Process Theory (NPT), are intended to assess the feasibility of embedding the intervention within the NHS. Have the authors considered using focus groups alongside individual interviews to capture a broader range of organizational dynamics and collaborative elements?

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Jul 14;20(7):e0323275. doi: 10.1371/journal.pone.0323275.r002

Author response to Decision Letter 1


6 Dec 2024

Editor:

Thank you for selecting these reviewers. Please find our responses below.

We must raise concerns about the review provided by Reviewer 3. The format and language of the review coupled with the irrelevance of the many of the comments to process evaluations leads us to believe they have used an AI/LLM to generate their response. One possible implication of this is that they have breached confidentiality by providing access to this confidential manuscript to a third party. This would of course be grounds for legal action on the part of the authors. It is disappointing that this has not been picked up by the editorial office.

We are grateful to the other reviewers for their diligent input.

Reviewer #1: Many thanks for taking the time to review our manuscript and providing your input.

1.Can the authors clarify the rationale behind the chosen mixed-methods process evaluation design and its alignment with the study's objectives?

The mixed-methods design was chosen in line with the latest guidance concerning the evaluation of complex interventions and process evaluations. This led us to use the UK Medical Research Council and Linnan and Steckler evaluation frameworks as stated on lines 172-173. It would not be possible to address the various aims of this process evaluation without employing a combination of qualitative and quantitative methods as some aims are incompatible with a particular type of methods. Qualitative methods are often required for questions of understanding. Quantitative methods are well suited to descriptive questions which, given the scale of this evaluation and inevitable resource constraints, offer efficient means of collecting data.

Furthermore, in the seminal paper by Oakley et al 2006 in The BMJ it is clearly articulated that in process evaluations of randomised controlled trials should be informed by both quantitative and qualitative data - https://pmc.ncbi.nlm.nih.gov/articles/PMC1370978/

2. How do the authors ensure the consistency (fidelity) of training and intervention delivery across different sites, especially since the trial involves multiple healthcare professionals and exercise professionals?

The STAMINA trial is a pragmatic study whereby healthcare professionals and exercise professionals (i.e. non-research staff) will deliver the interventions in a real-world situation. As such the potential for variation in the delivery of training and the intervention is to be anticipated. Fidelity is conceptualised in this study according the National Institute of Health Behavioural Change Consortium framework (line 25, line 286 – reference 28) and we sought to preserve fidelity according to the guidance in this framework.

With regards to the fidelity of training – in cases of both healthcare professional training and exercise professional training standardised training packages were used by an intentionally small number of training facilitators using a purpose-designed training manual. In the case of the exercise professional training, all training was delivered by one facilitator. This was not guaranteed by design but will be demonstrated in the published results (see facilitator characteristics in Table 1).

With regards to fidelity of delivery – Healthcare professionals received physical prompts to take to clinic visits to facilitate delivery of the target behaviours in practice. Exercise professionals received a detailed intervention delivery manual with step-by-step instructions regarding the target behaviours. Further details of these are intended to be published in other works.

3. The study proposes integrating findings from different methods (e.g., interviews, process outcomes). Can the authors provide more specific details about how they plan to triangulate these findings to draw meaningful conclusions?

There are several ways by which the design of this evaluation gives us the opportunity to integrate findings and triangulate data from different sources. Firstly, from Table 1 it is clear that there are many instances where data from multiple sources are integrated to provide a more comprehensive insight into the behaviour of individual process evaluation component. Next, the relationship between these components and how they are presumed to act in a causal chain of events that produce the intervention outcomes is described in the programme logic (Fig 1). From this we have a theoretical basis upon which to consider the behaviour of individual components was influenced by others. It is less clear a priori exactly how this will emerge because there are many possible ways that the process data could deviate from a perfectly homogenous prespecified model.

As a simplified single example of how data might be integrated, we may observe that there are high rates of dropout from the intervention that vary by site. Interview data from participants healthcare professionals and/or exercise professionals might elucidate some factors exist may have negative influences on the acceptability of the intervention.

It is probably not worthwhile to try to anticipate all examples of how we might integrate findings because there are too many possibilities. To put it another way there is a both a large potential problem space and solution space meaning that attempting to concisely define all possible problems and potential solutions is impossible.

For the reasons explained above, there are very, very few examples of how process evaluation protocols specify how their results would be integrated. Here is the best example we can find of how this a process evaluation protocol would address your question – clearly there are limitations to the level of detail that can be provided in a such a protocol:

“Integration of the qualitative and quantitative case study data regarding implementation of different components of the intervention will allow detailed evaluation of the quality of intervention implementation in each case study site. For example, quantitative data relating to the number and type of patient problems identified for the agenda and included in the health plan can be integrated with observational data about how clinicians addressed agenda setting and health planning. The additional integration of interview data about patients’ and clinicians’ experiences of reviews will provide in-depth insight into those processes.”

Mann C, Shaw A, Guthrie B, et al. Protocol for a process evaluation of a cluster randomised controlled trial to improve management of multimorbidity in general practice: the 3D study. BMJ Open 2016;6:e011260. doi:10.1136/bmjopen-2016-011260

4. The authors mention some limitations of their approach, particularly regarding fidelity and the absence of audio recordings of healthcare professional-patient interactions. Could the authors elaborate on alternative strategies to mitigate the effects of these limitations?

There is limited evidence-based mitigation possible for mitigated the limitations of this particular method of data collection. We can’t know confidently what the effect the HCPs had on patient behaviours, but we could be explore this in future implementation work if the trial has a positive outcome. Some information regarding professional-patient interactions may be picked up in patient interviews – we explicitly asked patients in interviews about their experiences with HCPs and HCP target behaviours.

Reviewer #2: Many thanks for taking the time to review our manuscript and providing your input.

Well designed evaluation study protocol and well written manuscript. Congratulations. Few comments/suggestions are attached

Page 3-Line no-53-56: just wondering whether the listed adverse events would be evaluated pre and post intervention

Thank you for your kind comment. Only some of these adverse consequences of ADT are evaluated as part of the trial including fatigue, adiposity indices, body mass, sexual dysfunction. Some of these adverse consequences are not suitable to study over only the 12-month follow-up period of this study. Note that the measurement of these outcomes is addressed by the trial protocol and not this process evaluation.

Page 7 Line no. 150 and 19 and line number -Implementation team doing the process evaluation-Need to incorporate suggestion to strengthen the manuscript-Are these going to be evaluated pre and post intervention?

Though it is unclear what is being asked here, please refer to Fig 2 to see the timelines for evaluation of the process evaluation components in relation to intervention delivery.

Page.7: table numbering to be corrected for column as currently number continues from 1 to 59. Each column and row should start with 1

The numbering in Table 1 deliberately continues from 1-59 to facilitate cross referencing of these data sources in Table 2. An alternative numbering of A1, B2, etc could be used instead.

Page 11 -Line no.163: Omission to be rectified-Add ADT

Thank you for spotting this formatting error, it has now been rectified.

Page 15 Table 4: Suggestion for inclusion--Facilitating factors that helped/induced sustenance of the participants in the programme could be added

We appreciate the suggestion to include this factor, but we would like to remain consistent within the externally defined theoretical framework that we are applying – see reference 26 below. In any case topic guides for the interviews have already been approved as part of the ethics application and it may not be timely to request and amendment. The framework was semi-structured so elements related to sustenance might have been captured and can discussed in the study results if appropriate.

Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017 Jan 26;17(1):88.

Page 15 Table 4: Repetition to be deleted-Affective attitude and burden

Good spot – now removed.

Page 15 Line no. 214 to 215: requires rewording for clarity. Cannot understand the statement made. No. of sites will be reduced to maintain treatment fidelity?

Original statement:

Treatment fidelity is particularly important for multi-site studies to understand if the intervention is operationalised in the same way across sites and minimise site by treatment interactions.

Reworded statement: In multi-site studies, it is particularly important to assess treatment fidelity because if treatment effects vary by site, we can observe whether this is related to variations in the delivery of treatment.

Page 17 Line 266: required additional information. If participant doesnt come for follow up intervention, what steps would be taken-could be described

This question relates more to the trial than the process evaluation and has been addressed in the trial protocol:

“Intervention adherence will be monitored weekly by the research team at SHU by reviewing SLI participants’ attendance at supervised exercise sessions, to identify those who have dipped below 75% attendance. CESs at each NH site will upload data relating to attendance and completion of aerobic and resistance exercise components of the SLI after each session using a REDCap web-based reporting software. Researchers will download, compile, and clean the data on a weekly basis. The database will track adherence relative to the number of prescribed sessions to date and produce “alerts” once a SLI participant drops below 75% adherence. This alert with suggested actions will be sent onto the NH fitness manager who will identify and deliver behavioural support in line with the COM-B [30] model of behaviour change (i.e. data verification, identify required behavioural support and deliver behavioural support). If a participant’s attendance remains below 75%, a maximum two further alerts are sent. A record of all alerts sent and subsequent actions will be maintained.”

McNaught, E., Reale, S., Bourke, L. et al. Supported exercise TrAining for Men wIth prostate caNcer on Androgen deprivation therapy (STAMINA): study protocol for a randomised controlled trial of the clinical and cost-effectiveness of the STAMINA lifestyle intervention compared with optimised usual care, including internal pilot and parallel process evaluation. Trials 25, 257 (2024). https://doi.org/10.1186/s13063-024-07989-y

Reviewer #3: The manuscript outlines a protocol for a process evaluation embedded within a lifestyle intervention trial for prostate cancer patients undergoing androgen deprivation therapy (ADT). This evaluation covers recruitment, fidelity, intervention reach, and organizational aspects. Below are some points for clarification and consideration to enhance the transparency and robustness of the evaluation.

Major Comments:

Validity of the Analysis for Endpoints Based on Questionnaires:

The primary endpoints, quality of life and fatigue, rely on self-reported questionnaires (FACT-Prostate and FACIT-Fatigue), which, while validated, may be subject to response bias and measurement variability. How will the study account for the inherent subjectivity and potential variability in self-reported data? Have any sensitivity analyses been considered to assess the robustness of findings against these potential biases?

This comment is relevant to the design of the trial endpoints but not the objectives of the process evaluation discussed herein.

Timing and Schedule of Endpoint Collection:

The manuscript mentions that process data will be collected at various points during and after the intervention, but it is not entirely clear how this aligns with the timing of the main trial endpoints (e.g., quality of life measured at 12 months). Could the authors clarify the alignment of process data collection with primary trial outcomes? Additionally, given the 12-month follow-up, how will potential attrition bias be managed, particularly in relation to the consistency of data collected from self-reported questionnaires over time?

Again, this comment is relevant to the design of the trial endpoints but not the objectives of the process evaluation discussed herein.

Fidelity and Intervention Delivery:

The manuscript highlights fidelity assessment as a key component of the process evaluation, utilizing audio recordings, direct observations, and checklists. Could the authors elaborate on how fidelity will be quantified and reported? Will there be a specific scoring system to assess adherence to intervention components? Additionally, how will deviations from the intervention protocol be addressed within the analysis framework?

Specific information about how fidelity is being assessed and scored is described in details in the fidelity analysis section – lines 292-296. Deviations from the intervention protocol are a matter for the trial analysis and not the process evaluation and will be described in detail in the statistical analysis plan which is awaiting publication. Where patterns of poor treatment fidelity occur, they will be reported as part of this process evaluation but not necessarily intervened upon.

Bias in Self-Reported Data:

While the process evaluation is comprehensive, it does not address potential bias in the subjective, self-reported data (e.g., physical activity and quality of life outcomes) and qualitative interviews. How will such bias be accounted for in the study, and what impact might this have on the interpretation of the study’s conclusions?

Again, this comment is relevant to the design of the trial endpoints but not the objectives of the process evaluation discussed herein.

Minor Comments:

Understanding Trial Recruitment Performance:

The process evaluation likely involves tracking recruitment metrics, assessing participant demographics, and gathering qualitative feedback from recruitment staff. Will the evaluation also examine factors that may hinder recruitment, such as through feedback from recruitment staff and potential participants who declined to participate?

As stated in Table 1 (58) and Table 3 interview data from healthcare professionals will explore topics such as this. In Table 1 (4) we report that we will collect data about reasons for declining to take part from participants.

Describing Intervention Reach, Dose Delivered, and Dose Received:

Intervention reach, dose delivered, and dose received will be assessed through

Attachment

Submitted filename: Plos response.docx

pone.0323275.s005.docx (31.2KB, docx)

Decision Letter 1

Xing-Xiong An

PONE-D-24-40667R1Process evaluation for the STAMINA randomised controlled trial: a protocolPLOS ONE

Dear Dr. Ibeggazene,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 01 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Xing Xiong, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: It makes sense, from your explanation, to use continuous numbers in table 1, from 1 to 59. So please keep it and not change it to A1, B2, etc which would be more complex.

However, one clarification is requested:

1. "Page 7 Line no. 150 and 19 and line number -Implementation team doing the process evaluation-Need to incorporate suggestion to strengthen the manuscript-Are these going to be evaluated pre and post intervention?

Though it is unclear what is being asked here, please refer to Fig 2 to see the timelines for evaluation of the process evaluation components in relation to intervention delivery."

To clarify my query-This is regarding using implementation team for process evaluation. Though this is not ideal, funding limitation is an understandable reason for this compromise, which has already been mentioned as a limitation. What my suggestion regarding this is to add few precautions/strategies that would be undertaken to reduce bias in process evaluation reporting.

Reviewer #3: Thank you for addressing all the comments.

The responses adequately address the reviewer’s concerns and provide relevant updates to the manuscript. The authors demonstrate an awareness of the study’s exploratory nature and the inherent limitations, which is appropriate for the study design.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Jul 14;20(7):e0323275. doi: 10.1371/journal.pone.0323275.r004

Author response to Decision Letter 2


20 Mar 2025

Reviewer #2: It makes sense, from your explanation, to use continuous numbers in table 1, from 1 to 59. So please keep it and not change it to A1, B2, etc which would be more complex.

However, one clarification is requested:

1. "Page 7 Line no. 150 and 19 and line number -Implementation team doing the process evaluation-Need to incorporate suggestion to strengthen the manuscript-Are these going to be evaluated pre and post intervention?

Though it is unclear what is being asked here, please refer to Fig 2 to see the timelines for evaluation of the process evaluation components in relation to intervention delivery."

To clarify my query-This is regarding using implementation team for process evaluation. Though this is not ideal, funding limitation is an understandable reason for this compromise, which has already been mentioned as a limitation. What my suggestion regarding this is to add few precautions/strategies that would be undertaken to reduce bias in process evaluation reporting.

Thank you for the clarification. We believe the main strategy that we are able to employ to reduce reporting biases is to publish this protocol as now described on Pg 27, L313-317.

“….which has the potential to create biases in the collection and reporting of process evaluation data. In publishing this protocol, we intend to mitigate against the impact of these potential biases by acknowledging their potential in the data collection process for and by making explicit what data is to be collected, how each data type will be used to describe specific process evaluation components and how the process evaluation components and frameworks relate to each other.”

Publishing process evaluation protocols is still a rare practice with no guidelines though it is becoming more common.

Other methods to reduce reporting biases include inclusion of the interview topic guides in the Supplementary materials. We have also already stated that “At least 20% of data will be independently double or triple coded” with regard to interview analysis. We also have made clear where our findings will be triangulated using data from multiple sources (table 1).

Reviewer #3: Thank you for addressing all the comments.

The responses adequately address the reviewer’s concerns and provide relevant updates to the manuscript. The authors demonstrate an awareness of the study’s exploratory nature and the inherent limitations, which is appropriate for the study design.

Attachment

Submitted filename: Plos response 2.docx

pone.0323275.s006.docx (17.8KB, docx)

Decision Letter 2

Xing-Xiong An

Process evaluation for the STAMINA randomised controlled trial: a protocol

PONE-D-24-40667R2

Dear Dr. Ibeggazene,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Xing-Xiong An, M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Your paper has now been approved by the reviewer, and I am pleased to inform you that your manuscript can be accepted for publication now.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thank you for revising the manuscript to address the queries and suggestions. I donot have any more queries.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: No

**********

Acceptance letter

Xing-Xiong An

PONE-D-24-40667R2

PLOS ONE

Dear Dr. Ibeggazene,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Xing-Xiong An

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. ADT symptom index.

    (DOCX)

    pone.0323275.s001.docx (25.6KB, docx)
    S2. Appendix 1–5.

    (DOCX)

    pone.0323275.s002.docx (37.9KB, docx)
    S3. STAMINA_Topic_Guide_Interviews_v5.0_20230705.

    (DOCX)

    pone.0323275.s003.docx (42.7KB, docx)
    Attachment

    Submitted filename: Plos response.docx

    pone.0323275.s005.docx (31.2KB, docx)
    Attachment

    Submitted filename: Plos response 2.docx

    pone.0323275.s006.docx (17.8KB, docx)

    Data Availability Statement

    No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES